The federal government is clawing back $11.4 billion in COVID-19 funding, a move that could affect local and state public health efforts across the US.

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

The objective response rate was 45.4% with SC pembrolizumab and 42.1% with IV pembrolizumab. Subcutaneous (SC) pembrolizumab appears to be non-inferior to standard intravenous (IV) pembrolizumab ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

(HealthDay News) — Grants from the National Institutes of Health (NIH) that were funding research on LGBTQ+ health have been canceled by the US government, alarming scientists who say the move will ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

The pair take on their new roles in the wake of mass firings — and subsequent rehirings — at the NIH and FDA, with the threat of additional layoffs looming. The Senate has confirmed new ...